Literature DB >> 28697853

Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy.

Victoria Dunne1, Mihaela Ghita1, Donna M Small2, Caroline B M Coffey1, Sinead Weldon2, Clifford C Taggart2, Sarah O Osman3, Conor K McGarry3, Kevin M Prise1, Gerard G Hanna4, Karl T Butterworth5.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate the impact of ATR inhibition using AZD6738 in combination with radiotherapy on the response of non-small cell lung cancer (NSCLC) tumour models and a murine model of radiation induced fibrosis.
MATERIALS AND METHODS: AZD6738 was evaluated as a monotherapy and in combination with radiation in vitro and in vivo using A549 and H460 NSCLC models. Radiation induced pulmonary fibrosis was evaluated by cone beam computed tomography (CBCT) and histological staining.
RESULTS: AZD6738 specifically inhibits ATR kinase and enhanced radiobiological response in NSCLC models but not in human bronchial epithelial cells (HBECs) in vitro. Significant tumour growth delay was observed in cell line derived xenografts (CDXs) of H460 cells (p<0.05) which were less significant in A549 cells. Combination of AZD6738 with radiotherapy showed no significant change in lung tissue density by CBCT (p>0.5) and histological scoring of radiation induced fibrosis (p>0.5).
CONCLUSION: Inhibition of ATR with AZD6738 in combination with radiotherapy increases tumour growth delay without observable augmentation of late radiation induced toxicity further underpinning translation towards clinical evaluation in NSCLC. Crown
Copyright © 2017. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AZD6738; Ataxia telangiectasia related-3 (ATR); DNA damage response; Fibrosis; Non-small cell lung cancer (NSCLC); Small animal radiotherapy research platform (SARRP)

Mesh:

Substances:

Year:  2017        PMID: 28697853     DOI: 10.1016/j.radonc.2017.06.025

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

1.  ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.

Authors:  Magnus T Dillon; Katharina F Bergerhoff; Malin Pedersen; Harriet Whittock; Eva Crespo-Rodriguez; Emmanuel C Patin; Alex Pearson; Henry G Smith; James T E Paget; Radhika R Patel; Shane Foo; Galabina Bozhanova; Chanthirika Ragulan; Elisa Fontana; Krisha Desai; Anna C Wilkins; Anguraj Sadanandam; Alan Melcher; Martin McLaughlin; Kevin J Harrington
Journal:  Clin Cancer Res       Date:  2019-02-15       Impact factor: 12.531

Review 2.  Preclinical models of radiation-induced lung damage: challenges and opportunities for small animal radiotherapy.

Authors:  Mihaela Ghita; Victoria Dunne; Gerard G Hanna; Kevin M Prise; Jaqueline P Williams; Karl T Butterworth
Journal:  Br J Radiol       Date:  2019-02-13       Impact factor: 3.039

Review 3.  Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.

Authors:  Pooja Karukonda; Diana Odhiambo; Yvonne M Mowery
Journal:  Mol Carcinog       Date:  2021-12-29       Impact factor: 4.784

Review 4.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Authors:  Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Nat Rev Clin Oncol       Date:  2021-11-24       Impact factor: 66.675

5.  Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system.

Authors:  Matthew C Walb; Brett L Carlson; Jann N Sarkaria; Erik J Tryggestad
Journal:  Br J Radiol       Date:  2018-11-14       Impact factor: 3.039

6.  CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells.

Authors:  Hang Li; Jun Che; Mian Jiang; Ming Cui; Guoxing Feng; Jiali Dong; Shuqin Zhang; Lu Lu; Weili Liu; Saijun Fan
Journal:  Cell Commun Signal       Date:  2020-09-17       Impact factor: 5.712

Review 7.  Integrating Small Animal Irradiators withFunctional Imaging for Advanced Preclinical Radiotherapy Research.

Authors:  Mihaela Ghita; Kathryn H Brown; Olivia J Kelada; Edward E Graves; Karl T Butterworth
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639

8.  Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.

Authors:  Rüveyda Dok; Mary Glorieux; Marieke Bamps; Sandra Nuyts
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

9.  CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.

Authors:  Gerard M Walls; Jamie B Oughton; Anthony J Chalmers; Sarah Brown; Fiona Collinson; Martin D Forster; Kevin N Franks; Alexandra Gilbert; Gerard G Hanna; Nicola Hannaway; Stephen Harrow; Tom Haswell; Crispin T Hiley; Samantha Hinsley; Matthew Krebs; Geraldine Murden; Rachel Phillip; Anderson J Ryan; Ahmed Salem; David Sebag-Montefoire; Paul Shaw; Chris J Twelves; Katrina Walker; Robin J Young; Corinne Faivre-Finn; Alastair Greystoke
Journal:  Clin Transl Radiat Oncol       Date:  2020-09-22

10.  Long non-coding RNA ANRIL promotes homologous recombination-mediated DNA repair by maintaining ATR protein stability to enhance cancer resistance.

Authors:  Lei Liu; Yuanyuan Chen; Yijuan Huang; Kun Cao; Tingting Liu; Hui Shen; Jianguo Cui; Bailong Li; Jianming Cai; Fu Gao; Yanyong Yang
Journal:  Mol Cancer       Date:  2021-07-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.